找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: New Therapies in Advanced Cutaneous Malignancies; Piotr Rutkowski,Mario Mandalà Book 2021 The Editor(s) (if applicable) and The Author(s),

[復(fù)制鏈接]
樓主: Mosquito
11#
發(fā)表于 2025-3-23 11:10:46 | 只看該作者
12#
發(fā)表于 2025-3-23 14:31:09 | 只看該作者
13#
發(fā)表于 2025-3-23 22:05:05 | 只看該作者
Dabrafenib and Trametinibta confirming significant improvement in overall survival and progression-free survival over vemurafenib therapy or dabrafenib alone. The next indication in melanoma for the combination of these drugs is adjuvant therapy, which was approved on the basis of long-term outcomes of study resulting in a
14#
發(fā)表于 2025-3-23 22:42:31 | 只看該作者
15#
發(fā)表于 2025-3-24 05:57:51 | 只看該作者
16#
發(fā)表于 2025-3-24 09:26:20 | 只看該作者
Vismodegib and differentiation. Hh pathway is inactive in most normal adult tissues, and this pathway reactivation is involved in the pathogenesis of several malignancies like basal cell carcinoma. Vismodegib has been approved for locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy
17#
發(fā)表于 2025-3-24 12:34:50 | 只看該作者
18#
發(fā)表于 2025-3-24 17:57:34 | 只看該作者
19#
發(fā)表于 2025-3-24 21:10:37 | 只看該作者
Nivolumab in Melanoma: An Overview of Medical Literature and Future Perspectivesand adjuvant treatment of melanoma. The first checkpoint inhibitor to be approved by FDA and EMA for treatment of melanoma was ipilimumab, a human cytotoxic T-lymphocyte antigen 4 (CTLA-4) antibody, based on proven benefit in terms of overall survival and recurrence-free survival in advanced and ear
20#
發(fā)表于 2025-3-25 00:41:36 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-11 03:09
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
张家界市| 关岭| 娄烦县| 特克斯县| 武夷山市| 德化县| 南川市| 东至县| 东阿县| 台中市| 右玉县| 洛川县| 原阳县| 荣昌县| 唐山市| 合阳县| 衡南县| 吉木萨尔县| 沧州市| 宜君县| 宁武县| 丽江市| 金阳县| 夏津县| 谷城县| 柏乡县| 泊头市| 肇东市| 繁峙县| 内丘县| 溆浦县| 丹东市| 铜鼓县| 绥棱县| 临夏市| 龙川县| 托克逊县| 玉门市| 兴城市| 长汀县| 株洲县|